Shire PLC (LON:SHP)‘s stock had its “buy” rating reiterated by Shore Capital in a research note issued on Tuesday.

A number of other equities analysts have also recently weighed in on the company. Liberum Capital decreased their price target on Shire PLC from GBX 4,900 ($63.61) to GBX 4,400 ($57.12) and set a “hold” rating for the company in a report on Friday. Barclays PLC cut Shire PLC to an “equal weight” rating in a report on Friday. Berenberg Bank restated a “buy” rating and issued a GBX 6,000 ($77.89) price target on shares of Shire PLC in a report on Wednesday, August 9th. Jefferies Group LLC decreased their price target on Shire PLC from GBX 5,600 ($72.70) to GBX 5,250 ($68.16) and set a “buy” rating for the company in a report on Monday, August 7th. Finally, Beaufort Securities restated a “long term buy” rating and issued a GBX 4,900 ($63.61) price target (down previously from GBX 6,200 ($80.49)) on shares of Shire PLC in a report on Friday, August 4th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 5,907.88 ($76.70).

Shares of Shire PLC (LON:SHP) opened at 3858.50 on Tuesday. The stock’s market capitalization is GBX 34.97 billion. The stock has a 50 day moving average of GBX 4,185.84 and a 200 day moving average of GBX 4,520.51. Shire PLC has a 12-month low of GBX 3,787.00 and a 12-month high of GBX 5,377.00.

ILLEGAL ACTIVITY WARNING: “Shire PLC (LON:SHP) Given “Buy” Rating at Shore Capital” was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at

In other news, insider Dominic Blakemore acquired 152 shares of Shire PLC stock in a transaction that occurred on Friday, June 30th. The shares were purchased at an average cost of GBX 4,255 ($55.24) per share, for a total transaction of £6,467.60 ($8,396.21).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.